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Abstract
ANCA-associated vasculitides (AAV) comprise a group of systemic vasculitides characterized by inflammation of small-sized 
blood vessels leading to multi-organ involvement. The worldwide annual incidence of AAV ranges from 1.2 to 3.3 cases per 
100 000 individuals with a prevalence of 4.6–42.1 cases per 100 000 individuals. The prevalence of AAV is geographically 
heterogeneous; therefore, regional epidemiological studies can be more informative to improve health care systems. Even 
though clinicians are aware that the healthcare burden and the risk of hospitalization of AAV appear high, data on hospitali-
zation and cost of illness due to AAV are still scarce or even lacking. This study aims to characterize the economic burden 
of AAV in Friuli Venezia Giulia (FVG), Italy. Thus, a retrospective study was conducted through the integration of many 
administrative health databases of the FVG as the source of information. From data integration, we estimated that more 
than two-thirds of AAV patients showed at least one hospitalization in their medical history, most frequently caused by the 
disease itself or superimposed infections. Around 10% of patients developed end-stage renal disease. In an 8-year follow-up, 
the overall healthcare cost was € 1,215,078, corresponding to € 6,168 patient-year. ANCA-positive patients showed much 
higher costs than ANCA-negative patients did. Overall, AAV are rare diseases, but imply very high healthcare costs. Early 
diagnosis and optimal treatment probably still remain unmet needs for AAV.
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Introduction
ANCA-associated vasculitides (AAV) are a group of sys-
temic vasculitides characterized by inflammation of small-
sized blood vessels leading to multi-organ involvement 
[1–5]. AAV include three major clinic-pathologic enti-
ties: granulomatosis with polyangiitis (GPA), microscopic 
polyangiitis (MPA), and eosinophilic granulomatosis with 
polyangiitis (EGPA) [6, 7]. AAV are rare diseases, with a 
worldwide annual incidence ranging from 1.2 to 3.3 cases 
per 100 000 individuals with a prevalence of 4.6–42.1 cases 
per 100 000 individuals [2]. Nevertheless, the incidence 
and prevalence of AAV have been progressively increasing 
in the last decades [2]. Among the subsets of AAV impor-
tant geographic differences have been observed [2, 8]. In 
Europe and Australia, a higher proportion of GPA versus 
MPA has been observed [2, 9]. Differently, in Asia (espe-
cially Japan), a higher proportion of MPA versus GPA has 
been observed [2]. The improvement in induction therapy 
has changed acute and life-threatening diseases to chronic 
ones associated with relapses, organ damage accumulation, 
and long-term immunosuppressive treatment side effects [2, 
10–16]. Therefore, AAV shows a high healthcare burden 
with a high risk of hospitalization. However, data on hos-
pitalization and the cost of illness due to AAV are still lim-
ited [3, 17]. Herein, we report the healthcare burden and the 
direct costs of the illness of AAV in Friuli Venezia Giulia 
(FVG), a region in the northeast of Italy. Importantly, two 
different data sources were used and compared, i.e., admin-
istrative healthcare databases and clinical databases. Second, 
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the costs of illness from a European healthcare system are 
information currently lacking for AAV in the literature.
Methods
The Regional Health Information System of FVG (about 1 
200 000 inhabitants) and clinical electronic chart records 
from our Hospital Clinic were used as the source of informa-
tion for this retrospective cohort study.
The system covers the entire regional population and 
includes various electronic health administrative databases 
that can be linked with one another on an individual basis 
through a unique encrypted ID identifier. The database of 
the regional potential health care beneficiaries (including 
demographic information and the residential history of all 
of the subjects living in the region), the hospital discharge 
database, the pharmaceutical prescription database, and the 
database of exemptions from medical charges were used for 
this study.
The hospital discharge database includes records from all 
of the regional hospitals (both public and private accredited 
to the public health system) and those regarding admissions 
of regional residents to extra-regional hospitals. The phar-
maceutical prescription database contains information on 
all of the medications prescribed by the physicians working 
in the public health system except those paid out-of-pocket. 
The database of exemptions from medical charges includes 
records on all of the potential health care beneficiaries who 
are entitled, because of low income, age, or chronic diseases, 
to receive free medications and outpatient specialist care. 
Notably, the Emergency Department (ED) database is acces-
sible, but, contrary to the procedures for hospital admissions 
or outpatient ambulatory care, the ED has no standard tariff 
associated with healthcare episodes. Thus, we have access 
to ED records, but they do not include any cost information.
The Italian Ministry of Health assigns codes to all of the 
diseases that entitle patients to exemptions. Currently, they 
include approximately 100 chronic and disabling diseases 
including the groups of rare diseases [18], where GPA, 
MPA, and EGPA are identified with the following codes: 
RG0070, RG0020, and RG0050, respectively. In the Italian 
healthcare system, only the specialists have the authorization 
to provide the exemption codes for rare diseases, and since 
the year 2010, a great effort has been made in our Region 
to keep the rare disease registry up-to-date, with the aim of 
filling such gap.
The cohort included all of the subjects living in FVG 
who received an exemption from medical charges because 
of a diagnosis of either GPA, MPA, or EGPA, accord-
ing to the corresponding exemption code from 2010 to 
2018. The subjects were observed from the date of first 
release of the exemption and followed until they moved 
outside the region, died, the outcome of interest occurred, 
or December 31, 2018, whichever came first. The outcome 
of interest was the event of hospitalization or death. Of 
note, we restricted the time frame of observation to the 
years from 2013 to 2018 as concerns the analysis on the 
whole regional population, i.e., starting from the year 
in which the laboratory analyses were centralized in the 
Laboratory of the Hospital of Udine, in particular for the 
autoimmunity tests, while we analyzed a longer time frame 
(2010–2018) when considering the province of Udine 
(about 530 000 inhabitants, the half of the whole regional 
population). For the best comparison, regarding the local 
retrospective cohort from our Clinic, we included in the 
analysis all the patients examined in Rheumatology Clinic 
of Udine (Referral Centre for AAV in FVG) who received 
diagnosis of GPA, MPA, and EGPA from 2010 to 2018.
Statistical analysis
The frequency distribution of the baseline cohort charac-
teristics and events of interest was calculated. The statisti-
cal significance of differences in the variable distribution 
between patients who experienced the event of interest 
and the others was assessed using the Chi-squared test for 
categorical variables, the t test for continuous variables 
with normal distribution, and Wilcoxon’s rank-sum test for 
continuous variables with non-normal distribution. Nor-
mality was assessed using the Kolmogorov–Smirnov test.
Kaplan–Meier curves were calculated to describe the 
event-free survival of patients, both overall and by treat-
ment groups. The log-rank test and Wilcoxon’s test were 
used to assess the significance of differences in survival. 
P < 0.05 was considered statistically significant.
All of the analyses were assessed using SAS v9.4 (SAS 
Institute Inc., Cary, NC, USA.).
Compliance with ethical standards
The authors assert that all of the procedures contribut-
ing to this work comply with the ethical standards of the 
relevant national and institutional committees on human 
experimentation and the Helsinki Declaration of 1975 as 
revised in 2008. This article does not contain any stud-
ies of human or animal subjects performed by any of the 
authors. Since this analysis was based on anonymous 
administrative data, patient informed consent and Ethical 
Committee approval were not required in Italy. As con-
cerns the analysis that was conducted on electronic clinical 
chart records, patients admitted to our Hospital were asked 
to sign an informed consent for using their own data for 
research purpose.
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Results
AAV epidemiology by integrated analysis 
of the administrative databases
Between the years 2013 and 2018, 103 patients with diag-
nostic code for AAV were identified in FVG, accounting 
for 8.58 cases/100 000 inhabitants (Table 1). Among these, 
patients with at least one hospitalization or death were 
74/103 (71.8%). 7/103 (6.8%) died during the observation 
period. The whole number of hospitalizations was 285 in 
74 patients (rate of 57 events per year), with an inpatient 
prevalence of 23.2 cases per 100 000 admissions. Fifty-
five out of 74 (74.3%) patients experienced more than one 
hospitalization. In most cases, the cause of hospitalization 
was a condition with high probability of being second-
ary to vasculitis (119/285, 41.8%) or the disease itself in 
more than half of cases (62/119, 52.1%, ICD-9-CM code 
446.4, “Wegener’s granulomatosis”) (Fig. 1). Infections 
were the second cause of hospitalization (26/285, 9.1%) 
(Fig. 1). In 10/103 patients (9.7%), end-stage renal disease 
(ESRD) was recorded as an event. The presence of at least 
one positivity for ANCA antibodies was documented in 
76/103 patients (73.8%), mainly in patients carrying GPA. 
Globally, ANCA positivity tended to be associated with a 
greater likelihood of an event (hospitalization/death) (HR 
1.75, 95% CI 0.97–3.16, p = 0.06, Log-Rank test), irre-
spectively from disease diagnosis and after correction for 
age and gender. The first event occurred in 50% of ANCA-
positive patients within 180 days (95% CI 84–297) from 
the diagnosis, while in 50% of ANCA-negative patients in 
859 days (95% CI 87–1695). Notably, six out of the seven 
deaths occurred in ANCA-positive patients.
For the province of Udine, 530 000 inhabitants served 
by the University Hospital of Udine and by the reference 
third-level center for rare rheumatologic diseases; labora-
tory results have been available since 2010. Thus, we evalu-
ated the cost of illness in patients suffering from AAV and 
residents in the province of Udine from 2010 to 2018. In 
the province, from 2010 to 2018, 57 patients (201 patient-
years) with AAV were identified. GPA, EGPA, and MPA 
were diagnosed in 20 (35.1%), 21 (36.8%), and 16 (28.1%) 
patients, respectively. They were ANCA-positive in 44/57 
(77.2%); of which GPA, EGPA, and MPA were diagnosed in 
18 (40.9%), 15 (34.1%), and 11 (25%) patients, respectively. 
The mean age at diagnosis was 54.5 (17.5) years. Again, 
the disease itself was the main cause of hospitalization in 
Table 1  Comparison between Regional Health Information System of Friuli Venezia Giulia and clinical electronic chart records from our Hospi-
tal Clinic
AAV ANCA-associated vasculitis, ANCA anti-neutrophil cytoplasmic antibodies, ESRD end-stage renal disease
AAV patients Administrative healthcare databases Clinical databases
Residents in Friuli Venezia Giulia Residents in the province of Udine Rheumatology Clinic of Udine
Period of observation 2013–2018 2010–2018 2010–2018
Mean (SD) or N (%)
N. Pts. AAV 103 57 58
Disease diagnosis (GPA; EGPA; 
MPA)
40 (38.8%); 39 (37.9%); 24 (23.3%) 20 (35.1%); 21 (36.8%); 16 (28.1%) 30 (51.7%); 19 (32.8%); 9 
(15.5%)
Mean age 55.1 (16.2) 54.5 (17.5) 57.8 (14.3)
ANCA positivity 76/103 (73.8%) 44/57 (77.2%) 47/58 (81)%
N. hospitalizations 285 126 82
Hospitalization rate (per year) 57 – 10.3
Pts. with at least one event (hospi-
talization or death)
74/103 (71.8%) – 47/58 (81%)
Pts. with ≥ 2 hospitalizations 55/74 (74.3%) – 18/47 (38.3%)
Hospitalization for disease itself 119/285 (41.8%) 60/126 (47.6%) 56/82 (68.3%)
Hospitalization for infective disease 26/285 (9.1%) – 9/82 (10.9%)
ESRD 10/103 (9.7%) – 5/58 (8.6%)
Death 7/103 (6.8%) 4/57 (7%) 6/58 (10.3%)
Mortality rate (per year) 1.4 0.5 0.75
GPA EGPA MPA
Estimated cost per patient-year (€) 5199 2329 4771
ANCA + ANCA-
Estimated cost per patient-year (€) 7058 2559
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almost half of the hospital discharges (60/126, 47.6%). Four 
patients died during the observation period due to vasculitis 
itself (1/4), pneumonia (2/4), or haematological malignancy 
(1/4). Time to the first event (hospitalization or death) was 
significantly lower in ANCA-positive AAV patients than 
in ANCA-negative AAV patients, ANCA-positive AAV 
patients showing a three times higher risk than ANCA-
negative patients (HR 3.38 95% CI 1.13–10.18, p = 0.03). 
Total estimated cost was € 1,215,078, corresponding to 
€ 6,168 per patient-year. Costs for ANCA-positive AAV 
patients were much higher than for ANCA-negative patients 
(€ 1,115,253 vs € 99,825, and € 7,058 per person-year vs 
€ 2,559 per person-year, respectively) (Fig. 2). GPA and 
MPA showed the highest costs if compared to EGPA [GPA: 
€ 239,168 (€ 5,199 per person-year) vs MPA: € 281,502 (€ 
4,771 per person-year) vs EGPA: € 214,287 (2,329 per per-
son-year), respectively] (Fig. 3). Interestingly, hospital medi-
cations and medications dispensed by hospital pharmacies 
for EGPA patients represent a minor burden of expenditure 
as compared to MPA and GPA, whereas costs for prescribed 
medications are higher for EGPA patients (Fig. 3). Finally, 
costs for hospitalization were the highest among the direct 
costs of illness [€ 734,957 (€ 3,731 per person-year) vs other 
costs € 480,121 (€ 2,437 per person-year)].
AAV epidemiology based on local clinical electronic 
chart records
Further detailed information on patients with AAV was 
obtained using data from the Rheumatology Clinic of Udine, 
Referral Centre for AAV in FVG. Using our database, 58 
patients (34 females, 24 males) with AAV diagnosis from 
2010 to 2018 were identified. The mean age at the diagnosis 
of disease was 57.8 (14.3) years. Patients’ diagnosis included 
GPA in 30 cases (51.7%), EGPA in 19 cases (32.8%), and 
MPA in 9 cases (15.5%). They were ANCA-positive in 47/58 
(81%), in particular 24/47 (51.1%) cANCA/PR3 and 23/47 
(48.9%) pANCA/MPO. The main characteristics of the 
patients are summarized in Table 2. Patients with at least 
one hospitalization were 47/58 (81%). Eighteen out of 47 
disease related, 119, 
42%
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Fig. 1  Distribution of the categories of main discharge diagno-
sis for 285 hospitalizations of patients with AAV in FVG (years 
2013–2018). the following ICD-9-CM codes were considered “dis-
ease related”: 287.0 “Allergic purpura”, 288.3 “Eosinophilia”, 381.4 
“Nonsuppurative otitis media, not specified as acute or chronic”, 
423.0 “Hemopericardium “, 437.4 “Cerebral arteritis”, 446.4 
“Wegener’s granulomatosis”, 447.6 “Arteritis, unspecified”, 473.0 
“Chronic maxillary sinusitis”, 473.2 “Chronic ethmoidal sinusitis”, 
518.3 “Pulmonary eosinophilia”, 580.4 “Acute glomerulonephri-
tis with lesion of rapidly progressive glomerulonephritis”, 582.4 
“Chronic nephritis with lesion of necrotizing glomerulitis”, 582.9 
“Chronic glomerulonephritis with unspecified pathological lesion in 
kidney”, 584.5 “Renal failure with (acute) tubular necrosis”, 375.53 
“Stenosis of lacrimal canaliculi”, 375.56 “Stenosis of nasolacri-
mal duct, acquired”, 381.10 “Chronic serous otitis media, simple or 
unspecified”, 420.90 “Acute pericarditis, unspecified”, 446.29 “Other 
specified hypersensitivity angiitis”, 478.74 “Stenosis of larynx”, 
519.19 “Unspecified disease of respiratory system”, 582.89 “Chronic 
glomerulonephritis with lesion of: exudative nephritis”
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(38.3%) patients experienced more than one hospitalization. 
The whole number of hospitalizations was 82 in 47 patients 
(10.3 events per year). The disease itself was the main 
cause of hospitalization in more than half of the hospital 
discharges [56/82 (68.3%)]; infections were the second one 
[9/82 (10.9%)]. 5/58 (8.6%) patients developed ESRD and 
6/58 (10.3%) patients died during the observation period. 
ANCA positivity seems to be associated with a greater 
likelihood of an event, i.e., hospitalization [67/82 (81.7%)] 
































Fig. 2  The overall estimated healthcare costs (€) per person-year for 57 AAV patients, residents in the province of Udine from 2010 to 2018, 



































Fig. 3  The overall estimated healthcare costs (€) per person-year for 57 AAV patients, residents in the province of Udine from 2010 to 2018, 
also divided into each entity (GPA, MPA, and EGPA)
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ANCA-negative showed a better outcome than persistently 
ANCA-positive patients did (Fig. 4).
Discussion
In the present study, we performed a global assessment of 
inpatient epidemiology and the economic burden of AAV in 
FVG (around 1 200 000 people) by integrating information 
coming from different sources, i.e., administrative healthcare 
databases and clinical databases (Table 1). This comparative 
analysis should be relevant for highlighting strengths and 
limitations of each source of data, and for addressing future 
researches in this field. Notably, cost estimation reported by 
us represents the first data available in the literature coming 
from a European healthcare system.
The management of AAV has evolved considerably in 
the recent decades, allowing improvements in outcomes 
and overall survival [19–22]. Nevertheless, the disease itself 
and, importantly, superimposed infections are still the main 
causes of hospitalization in AAV [3, 23]. In addition, still 
in the last decade, almost 10% of patients develop ESRD 
during the follow-up. Both the methodological approaches 
of our study led to this observation. Thus, the unmet needs 
of early diagnosis, in particular for renal involvement, and 
novel treatments, especially carrying significant steroid-
sparing effect, clearly emerged from these results [24, 25]. 
Second, the ANCA status was confirmed to be an important 
prognostic factor [14, 26]. ANCA-positive patients, in par-
ticular ANCA/PR3-positive patients, more frequently show 
a relapsing–remitting disease [14]. Mortality and hospitali-
zation rate were both significantly related to the presence of 
ANCA in our study. In addition, ANCA-positive patients 
showed a much shorter time to the first hospitalization than 
ANCA-negative patients, thus implying a more aggressive 
systemic disease and related higher level of immunosuppres-
sion. Again, both administrative data and clinical evaluation 
were strictly concordant on this point (Table 1). By contrast, 
the number of hospitalizations, even if in a different period, 
significantly differed between the administrative source and 
the clinical source of data, with the latter likely underesti-
mating the events. This highlights the possible bias coming 
from clinical charts, especially when the time of observation 
is very long (i.e., 8 years), and, on the other hand, it rein-
forces the validity of an integrated approach by combining 
administrative databases and clinical evaluation in long-term 
retrospective observational studies on rare diseases. Also, 
the lower prevalence which we reported of MPA, which is 
often an isolated renal vasculitis managed by nephrologists, 
reinforces this concept.
The total cost of illness in patients suffering from AAV 
and residents in the province of Udine from 2010 to 2018 
was € 1,215,078, corresponding to € 6168 patient-year. It 
was more than two times higher than that of patients with 
giant cell arteritis in the same area [27]. This estimation 
was the first one reported in the literature coming from a 
European healthcare system. The universal Italian healthcare 
system follows a tax-funded model similar to the Beveridge 
type, which is completely different from the insurance-based 
systems. With that premise, the substantially higher hospital 
costs recently reported by Ungprasert et al. from USA are 
not comparable with our results [3]. The main component 
of the total cost was represented by costs for hospitaliza-
tion, amounting to € 734,957 (€ 3731 per person-year). 
Notably, higher costs of illness for ANCA-positive patients 
were documented for the first time (Fig. 2) as well as for 
GPA and MPA if compared to EGPA (Fig. 3) (GPA: € 5199 
per person-year vs MPA € 4771 per person-year vs EGPA 
2329 per person-year, respectively), therefore implying a 
higher number of patients with limited disease or with a 
more favourable course of vasculitis in EGPA than in GPA 
or MPA [1, 28–31]. However, the association between EGPA 
with chronic asthma in the adult, that is often resistant to 
many treatments, may explain the higher costs for prescribed 
Table 2  Characteristics of 58 AAV patients followed by the Rheuma-
tology Clinic of Udine (2010–2018)
AAV ANCA-associated vasculitis, GPA granulomatosis with poly-
angiitis, EGPA eosinophilic granulomatosis with polyangiitis, MPA 
micropolyangiitis, BVAS Birmingham Vasculitis Activity Score, 
ENT ear-nose-throat involvement, ANCA anti-neutrophil cytoplasmic 
antibodies, PR3 proteinase 3, MPO myeloperoxidase. Variables are 
reported as mean ± SD or N (%)
Demography
Age, years 57.8 ± 14.3





 BVAS v3 13.9 ± 6.7
Baseline vasculitis involvement










 Positive ANCA 47 (81%)
 cANCA/PR3 24 (51.1%)
 pANCA/MPO 23 (48.9%)
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medications for EGPA patients. After vasculitis resolu-
tion, asthma remains severe in up to 50% of patients and 
incidence of isolated-asthma and rhinosinus exacerbations 
remains constantly high. In addition, in EGPA patients with 
asthma, long-term severe or uncontrolled asthma is asso-
ciated with baseline pulmonary and ear, nose, and throat 
manifestations but not with typical vasculitic features [32]. 
This observation further supports the consideration of EGPA 
as a separate entity among AAV.
This healthcare burden was expected in FVG consider-
ing the becoming into a chronic disease of AAV, thanks to 
improvements in treatment. Emerging evidence in other 
studies [10, 33] is the negative effect on patients’ physical 
and mental quality of life (QoL) of AAV, comparable to 
other chronic diseases. Current vasculitis disease assessment 
tools (BVAS v3 and VDI) are only weakly correlated with 
measures and variations of QoL [34, 35]. Interesting pros-
pects might be offered by AVV-patient-reported outcomes 
(PRO) questionnaires. The AAV-PRO questionnaire could 
be useful to assess the patient’s perspective on the burden 
of disease [36].
Strengths and limitations
The main strength of this examination is the achievement of 
largely homogeneous and overlapping results using health 
administrative databases, including, of note, even the costs 
estimated for hospital medications for each patient, and 
smaller clinical charts. Moreover, our prevalence estima-
tion by healthcare administrative databases (8–9 cases 
per 100 000 individuals) was close to that reported in the 
literature of around 2–13 cases per 100 000 individuals 
[37–39], as well as the inpatient prevalence of 23.2 cases 
per 100 000 admissions was in line to Li et al. [17]. The 
advantage of using regional informatics healthcare admin-
istrative databases is to obtain available information on 
patients’ outcomes as well as healthcare burden and costs in 
a long period, possibly minimizing missing data. The latter 
are not available with smaller clinical databases, which risk 
being less informative for retrospective observational studies 
comprising long-term follow-up. Although not in the present 
study area, validation studies on rheumatic diseases have 
been published with good confidence in systemic rheumatic 
diseases [40, 41]. In addition, a similar study performed in 
US applied the same methods [42].
A limitation of using administrative health databases is 
the impossibility to correlate the disease assessment tools, 
patients’ perception of QoL, and work ability status, with 
recorded events. However, a complementary clinical evalu-
ation would serve to overcome this limit of a depersonal-
ized disease description. Moreover, a preliminary analysis 
on work ability status in AAV patients from our cohort has 
been recently reported, demonstrating the importance of 
such evaluation as complementary to disease activity and 
damage in AAV [43]. Also, our work did not allow us to 
attribute a different impact on costs to different treatment 
regimens. Probably, more information than that available 











N. Hospitalizaons 15 14 53 82
ESRD 0 0 5 5
Death 1 0 5 6
n Major Relapses 0 2 15 17
N. Hospitalizaons ESRD Death n Major Relapses
Fig. 4  Numbers of events in the 58 AAV patients followed by the Rheumatology Clinic of Udine (2010–2018). The patients have been divided 
into three categories: patients persistently ANCA-positive, patients becoming ANCA-negative, and patients ANCA-negative
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from retrospective cohorts based on administrative databases 
would be required to assess the impact of different treatment 
strategies employed on cost of illness. Controlled studies 
could more properly address this issue, by avoiding pos-
sible confounders. In addition, even if we have access to ED 
records, they do not include any cost information, as stated 
in the methods, and thus, our analysis did not consider the 
economic burden related to ED admission.
Conclusion
Even if rare, AAV are diseases showing a high level of 
economic source consumption for the healthcare system. 
The disease itself and the infectious complications during 
treatment still remain the main causes of hospitalization 
and related costs. The ANCA status seems to influence the 
outcome and the costs of illness greatly. EGPA seems to be 
a separate entity, also for its healthcare cost profile. Overall, 
the integration between healthcare administrative databases 
and clinical charts may draw the best portrait of these rare 
diseases, when considering a long time of observation.
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